Zacks Investment Research cut shares of Maximus (NYSE:MMS) from a buy rating to a hold rating in a research note published on Thursday morning.
According to Zacks, “MAXIMUS, Inc. is an extremely dynamic and complex organization that offers government and industry a range of unique services, products, and solutions. The diverse services and products that MAXIMUS offers may be categorized into three groups: Government Program Management and Operations, Consulting, and Systems. Government Program Management and Operations focuses on having a measurable impact on the lives of the citizens we help government serve. The insights of MAXIMUS Consulting, and the technological innovations advanced through Systems, help government gain program efficiencies and pursue improvements that in turn benefit citizens. “
Other equities research analysts also recently issued reports about the company. Maxim Group restated a hold rating and set a $69.00 price objective (up from $66.00) on shares of Maximus in a research report on Thursday, February 8th. Canaccord Genuity restated a buy rating on shares of Maximus in a research report on Wednesday, December 27th. One equities research analyst has rated the stock with a sell rating and six have assigned a hold rating to the stock. Maximus currently has a consensus rating of Hold and a consensus price target of $66.60.
MMS stock traded down $0.09 during midday trading on Thursday, reaching $67.77. 29,716 shares of the company traded hands, compared to its average volume of 454,223. Maximus has a 52-week low of $57.81 and a 52-week high of $72.71. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.57 and a quick ratio of 2.57. The company has a market cap of $4,419.53, a PE ratio of 22.40, a price-to-earnings-growth ratio of 2.34 and a beta of 1.12.
Maximus (NYSE:MMS) last issued its quarterly earnings data on Thursday, February 8th. The health services provider reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.01. Maximus had a return on equity of 22.93% and a net margin of 8.99%. The business had revenue of $623.10 million for the quarter, compared to the consensus estimate of $624.36 million. During the same period in the prior year, the business posted $0.71 earnings per share. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. equities research analysts expect that Maximus will post 3.31 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 31st. Stockholders of record on Tuesday, May 15th will be issued a $0.045 dividend. The ex-dividend date is Monday, May 14th. This represents a $0.18 annualized dividend and a dividend yield of 0.27%. Maximus’s payout ratio is 5.94%.
In other news, General Counsel David Francis sold 3,600 shares of the stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $64.50, for a total value of $232,200.00. Following the sale, the general counsel now directly owns 10,017 shares in the company, valued at $646,096.50. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Russell A. Beliveau sold 1,000 shares of the stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $66.55, for a total value of $66,550.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 44,600 shares of company stock worth $3,009,650. Company insiders own 3.10% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Amundi Pioneer Asset Management Inc. bought a new position in Maximus in the fourth quarter worth approximately $163,000. Steward Partners Investment Advisory LLC bought a new stake in Maximus during the 4th quarter valued at $169,000. Capital One National Association bought a new stake in Maximus during the 4th quarter valued at $213,000. Zeke Capital Advisors LLC bought a new stake in Maximus during the 4th quarter valued at $222,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Maximus by 51.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,581 shares of the health services provider’s stock valued at $256,000 after acquiring an additional 1,214 shares in the last quarter. Hedge funds and other institutional investors own 96.72% of the company’s stock.
Maximus Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services programs in the United States, the United Kingdom, Australia, Canada, Singapore, and Saudi Arabia. The company's Health Services segment offers various BPS, appeals, and assessments, as well as related consulting services for state, provincial, and national government programs comprising Medicaid, Children's Health Insurance Program, the Affordable Care Act, Health Insurance British Columbia, the Health Assessment Advisory Service, and Preadmission Screening and Resident Reviews.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.